Phaseline

Targets › OPA1

OPA1 (Dynamin-like GTPase OPA1, mitochondrial): drug programs, companies and trials

3 programs from 3 companies in 5 trials: 2 Phase 1, 1 Phase 2, 1 Phase 4, 1 Phase 3; Ophthalmology, Other, Metabolic and endocrine; next expected readout Aug 2027.

Dynamin-related GTPase that is essential for normal mitochondrial morphology by mediating fusion of the mitochondrial inner membranes, regulating cristae morphology and maintaining respiratory chain function. Exists in two forms: the transmembrane, long form (Dynamin-like GTPase OPA1, long form; L-OPA1), which is tethered to the inner mitochondrial membrane, and the short soluble form (Dynamin-like GTPase OPA1,…. (UniProt, O60313)

Open in Phaseline: the race on OPA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stealth BioTherapeuticsElamipretide
OPA1-targeted peptide; mitochondrial function enhancer
OPA1Phase 4Barth Syndrome; Age Related Macular Degeneration (ARMD)Aug 2027
David MarcinekElamipretide
Mitochondrial targeting peptide; promotes optimal cristae remodeling and mitochondrial fun
OPA1Phase 2Aging, Healthy–
PYC TherapeuticsPYC-001
Peptide-phosphorodiamidate morpholino oligonucleotide (PMO) targeting OPA1
OPA1Phase 1OPA1 Gene MutationOct 2029

Conditions

OPA1 Gene Mutation (2) Aging, Healthy (1) Barth Syndrome (1) Age Related Macular Degeneration (ARMD) (1)

Modalities

protein or peptide (2), small molecule (1)

Companies

PYC Therapeutics (1) David Marcinek (1) Stealth BioTherapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.